Therapeutics

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Therapeutics

Boehringer Ingelheim and Google in R&D partnership

Boehringer Ingelheim has entered a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership combines Boehringer Ingelheim’s leading expertise in the field of computer-aided drug design and… Read More

#Editor's Choice #News

#Clinical trials #Immunology / Virology & Vaccines #Therapeutics

Peanut allergy biomarker study may lead to novel peanut vaccine candidate

Allergy Therapeutics, the specialty pharmaceutical company specialising in allergy vaccines, has announced that an ex-vivo biomarker study of blood samples from peanut allergy patients has begun at Imperial College London. The study aims to evaluate the group’s novel virus like particle (VLP) based peanut allergy vaccine candidate, to confirm its… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Therapeutics

Small molecule therapeutics: solubility with permeability to achieve better bioavailability

Technologies have been honed to overcome many of the challenges of administering BCS class II and IV small molecule therapeutics says John S. Vrettos, Senior Principal Scientist & Head of Formulation Development, Enteris BioPharma Small molecule drugs have traditionally dominated the treatment of human disease given their diverse mechanisms of… Read More

#Exclusive Content

#Biologics #Drug development #Drug discovery #Oncology #Therapeutics

International consortium awarded grant for first-in-class metastatic cancer treatment

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the… Read More

#Cancer Research #News

#Covid-19 #Organ-on-a-chip #Therapeutics

CN Bio and University of Melbourne collaborate on COVID-19 therapies

CN Bio has announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients. Harnessing CN Bio’s organ-on-a-chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung disease, often occurring… Read More

#Editor's Choice #News

#Antibodies #Therapeutics

Evotec and Sartorius partner with start-up focussed on therapeutic exosomes

Evotec and Sartorius have teamed up with recently established Curexsys, a German technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables the company to… Read More

#News

#CAR-T #Oncology #Therapeutics

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While… Read More

#Cancer Research #News #Videos

#AI / data analytics / healthtech / informatics #Therapeutics

Sitting down with…Orexo, digital therapeutic expert

Orexo recently launched the digital therapies deprexis and vorvida in the US. Lu Rahman talked to Nikolaj Sørensen, President and CEO about these therapies and the company’s expertise LR: Explain how digital therapies work and the type of conditions they are most suited to treat. NS: Digital therapeutics are evidence-based… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Therapeutics

How SARS-CoV-2 hijacks and damages lung cells offers insight for therapeutic targets

In a collaboration  involving the National Emerging Infectious Disease Laboratories (NEIDL), the Center for Regenerative Medicine (CReM), and the Center for Network Systems Biology (CNSB), scientists have reported the first map of the molecular responses of human lung cells to infection by SARS-CoV-2. By combining bioengineered human alveolar cells with… Read More

#Covid-19 #News

#Clinical trials #Drug candidates #Drug targets #Life sciences #Therapeutics

One Nucleus announces life science award shortlist

One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies with exciting developments. The finalists will pitch in the lead up to Genesis 2020 during which the winner will be announced. Companies and research organisations were nominated for their most important updates from the last… Read More

#News

#Genes #Therapeutics

Global programme to identify scarring gene may shape future therapies

A £1.5 million research programme that aims to achieve scar free healing within a generation has been launched by The Scar Free Foundation, the medical research charity which focuses solely on scarring. The five-year research study led by the University of Bristol will identify the gene(s) that causes scarring and… Read More

#News

#Clinical trials #Covid-19 #Therapeutics

The 100 year-old therapy that may prevent COVID-19 after exposure to the virus

Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients, such as the antiviral drug remdesivir or the corticosteroid dexamethasone,… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Drug discovery #Therapeutics

New flu therapy may help against COVID-19

A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. In an average year, more than 2 million people in the United States are hospitalised with the flu, and 30,000 to… Read More

#Covid-19 #News

#Antibodies #Therapeutics

FairJourney Biologics enters antibody discovery agreement with Pandion Therapeutics

FairJourney Biologics and IONTAS have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases. Pandion focuses on the development of innovative modular therapeutics using its… Read More

#News